<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE Fibroblast growth factor (FGF)-21 is highly expressed in the liver and regulates hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in rodents </plain></SENT>
<SENT sid="1" pm="."><plain>However, its role in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in humans remains to be defined </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to quantitate circulating plasma FGF-21 levels and examine their relationship with insulin sensitivity in subjects with varying degrees of <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS Forty-one subjects (8 lean with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance [NGT], 9 <z:mp ids='MP_0001261'>obese</z:mp> with NGT, 12 with impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> [IFG]/<z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> [IGT], and 12 type 2 diabetic subjects) received an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) and a hyperinsulinemic-euglycemic clamp (80 mU/m(2) per min) combined with 3-[(3)H] <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS Subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, subjects with IGT, and <z:mp ids='MP_0001261'>obese</z:mp> subjects with NGT were insulin resistant compared with lean subjects with NGT </plain></SENT>
<SENT sid="5" pm="."><plain>Plasma FGF-21 levels progressively increased from 3.9 +/- 0.3 ng/ml in lean subjects with NGT to 4.9 +/- 0.2 in <z:mp ids='MP_0001261'>obese</z:mp> subjects with NGT to 5.2 +/- 0.2 in subjects with IGT and to 5.3 +/- 0.2 in type 2 diabetic subjects </plain></SENT>
<SENT sid="6" pm="."><plain>FGF-21 levels correlated inversely with whole-body (primarily reflects muscle) insulin sensitivity (r = -0.421, P = 0.007) and directly with the hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> index (r = 0.344, P = 0.034) </plain></SENT>
<SENT sid="7" pm="."><plain>FGF-21 levels also correlated with measures of glycemia (fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [r = 0.312, P = 0.05], 2-h plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [r = 0.414, P = 0.01], and A1C [r = 0.325, P = 0.04]) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS Plasma FGF-21 levels are increased in insulin-resistant states and correlate with hepatic and whole-body (muscle) <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>FGF-21 may play a role in pathogenesis of hepatic and whole-body <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>